{
    "nct_id": "NCT03471078",
    "official_title": "Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers",
    "inclusion_criteria": "* Men and women greater than or equal to 18 years of age;\n* A diagnosis of ovarian, lung (small cell or non-small cell) or bladder cancer requiring systemic chemotherapy\n* Participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents:\n\n  * Nucleoside analog, including gemcitabine and fluorouracil;\n  * Carboplatin or cisplatin;\n  * Anthracycline; or\n  * Alkylating agent;\n* Participant experienced severe thrombocytopenia, defined as 2 platelet counts <50 x 109/L measured at least 24 hours apart, during the qualifying chemotherapy cycle, of their current chemotherapy regimen\n* ECOG performance status <=2\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant has experienced >=Grade 2 CIT other than during the current chemotherapy treatment regimen within 6 months of Screening;\n* Participant has any history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases;\n* Participant has received >2 previous lines of chemotherapy or is receiving whole brain radiation during the study treatment period;\n* Participant has a known medical history of genetic prothrombotic syndromes\n* Participant has a history of arterial or venous thrombosis within 3 months of screening;\n* Use of vitamin K antagonists;\n* Participant has previously received a thrombopoietin receptor agonist or recombinant human thrombopoietin for the treatment of CIT within 3 months of screening",
    "miscellaneous_criteria": ""
}